Product overview

Name MDL 100907
Alternative names Volinanserin
Purity >98%
Description Potent and selective 5-HT2A receptor antagonist
Write Your Own Review
You're reviewing:MDL 100907
Rate this item:

Biological Data

Biological description Potent and selective 5-HT2A receptor antagonist (Ki = 0.36 nM). Shows > 80-fold selectivity for 5-HT2A over other 5-HT receptor subtypes. Displays antipsychotic actions. Active in vivo.

Solubility & Handling

Storage instructions +4°C
Solubility overview Soluble in DMSO (100 mM) and in 0.05M HCl (50 mM)
Important This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.



More Info


More Info

Chemical Data

Purity >98%
Chemical name (R)-(+)-α-(2,3-Dimethoxyphenyl)-1-[2 -(4-fluorophenyl)ethyl]-4-piperinemethanol
Molecular Weight 373.46
Chemical structure MDL 100907 | [139290-65-6] Chemical Structure
Molecular Formula C22H28FNO3
CAS Number 139290-65-6
PubChem identifier 5311271
Source Synthetic
InChi InChI=1S/C22H28FNO3/c1-26-20-5-3-4-19(22(20)27-2)21(25)17-11-14-24(15-12-17)13-10-16-6-8-18(23)9-7-16/h3-9,17,21,25H,10-15H2,1-2H3/t21-/m1/s1
MDL number MFCD00909060
Appearance White solid

References for MDL 100907

References are publications that support the biological activity of the product
  • The 5-hydroxytryptamine2A receptor antagonist R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl-4-piperidinemethanol (M100907) attenuates impulsivity after both drug-induced disruption (dizocilpine) and enhancement (antidepressant drugs) of dif

    Ardayfio et al (2008) J Pharmacol Exp Ther 327(3) : 891-7
  • Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.

    Kehne et al (1996) J Pharmacol Exp Ther 277(2) : 968-81
  • Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.

    Sorensen et al (1993) J Pharmacol Exp Ther 266(2) : 684-91

3 Item(s)